Search results
SGLT2 Inhibitors in Acute Heart Failure
Added:
2 months ago
Viewpoint
Factor XIa Inhibitors’ Future Position in AF
Added:
1 year ago
Expert Opinion
Oral P2Y12 Inhibitors and Drug Interactions
Added:
11 months ago
Review Article
Added:
1 month ago
Source:
Radcliffe CVRM
A spectrum of primary aldosteronism, indicated by a higher aldosterone-renin ratio (ARR), may contribute to an increased risk of atrial fibrillation (AF) and ischaemic stroke in older adults, according to a new cohort study analysis.¹MethodologyThis prospective cohort analysis used data from the Atherosclerosis Risk in Communities (ARIC) study. The investigation included 3,477 community-dwelling…
View more
Added:
1 month ago
Added:
1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial…
View more
Added:
6 months ago
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an…
View more
